Twist Bioscience Corporation Common Stock (TWST)
Stock · NASDAQ · Health Care
$132.87as of 10/16/2026
Price chart
Active signals
TWST Signal Track Record
How signals performed across all stocks →What TWST's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 33 | +0.6% | 55% | September 24, 2026 |
| Bollinger Band Breakout | 28 | -0.9% | 46% | September 18, 2026 |
| Bollinger Band Breakdown | 21 | +3.8% | 57% | May 14, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +9.4% | 78% | December 29, 2025 |
| Any 20-session window (baseline) | +2.5% | 55% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CR…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 979
- Website
- www.twistbioscience.com/
Fundamentals
- 1-day range
- $130.98$145.05
- Market cap
- $6.84B
- P/E (trailing)
- —
- P/E (forward)
- -176.62
- EPS (trailing)
- $-2.22
- Dividend yield
- —
- Beta
- 2.17
- Avg. volume
- 2.16M
How Twist Bioscience Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Nov 17, 2025 · via SEC EDGAR / Finnhub
Forecasts
12 analyst ratings
Twist Bioscience Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- TWSTTwist Bioscience Corporation Common Stock$132.75▼ 8.13%Market cap $6.84BP/E —$23.3$219.71
- CGONCG Oncology Inc. Common stock$59.85▼ 3.25%Market cap $6.60BP/E —$35.8$80.97
- SRRKScholar Rock Holding Corporation Common Stock$39.9▼ 1.82%Market cap $6.31BP/E —$27.07$61.76
- IBRXImmunityBio Inc. Common Stock$9.18▼ 8.20%Market cap $7.76BP/E —$1.95$12.43
- IMVTImmunovant Inc. Common Stock$26.73▼ 2.84%Market cap $8.20BP/E —$16.6$45.42
- PCVXVaxcyte Inc. Common Stock$63.62▼ 2.53%Market cap $8.50BP/E —$39.87$90.75
- QGENQiagen N.V. Common Shares$46.13▼ 0.09%Market cap $8.60BP/E 22.92$32.53$57.82
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| TWST Twist Bioscience Corporation Common Stock | $6.84B | — | $132.75 | ▼ 8.13% | $23.3$219.71 |
| CGON CG Oncology Inc. Common stock | $6.60B | — | $59.85 | ▼ 3.25% | $35.8$80.97 |
| SRRK Scholar Rock Holding Corporation Common Stock | $6.31B | — | $39.9 | ▼ 1.82% | $27.07$61.76 |
| IBRX ImmunityBio Inc. Common Stock | $7.76B | — | $9.18 | ▼ 8.20% | $1.95$12.43 |
| IMVT Immunovant Inc. Common Stock | $8.20B | — | $26.73 | ▼ 2.84% | $16.6$45.42 |
| PCVX Vaxcyte Inc. Common Stock | $8.50B | — | $63.62 | ▼ 2.53% | $39.87$90.75 |
| QGEN Qiagen N.V. Common Shares | $8.60B | 22.92 | $46.13 | ▼ 0.09% | $32.53$57.82 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- TD Cowen Maintains Buy on Twist Bioscience, Raises Price Target to $190benzinga · 10/13/2026
- Humana, Evolution Metals & Technologies, Fastly And Other Big Stocks Moving Higher On FridayBenzinga · 10/9/2026
- This Generac Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayBenzinga · 10/8/2026
- Jefferies Initiates Coverage On Twist Bioscience with Hold Rating, Announces Price Target of $150Benzinga · 10/8/2026
- Twist Bioscience: Valuation Stretched As AI Drug Discovery Hype Outpaces RealitySeekingAlpha · 10/8/2026
- Barclays Maintains Overweight on Twist Bioscience, Raises Price Target to $215Benzinga · 10/7/2026
- NeoGenomics Sinks 12% on CEO Succession Plan Despite Revenue BeatYahoo · 10/6/2026
- Cathie Wood Loads Up On These Biotech Stocks After Strong Rallies – Unloads $18M Worth Of TWST SharesYahoo · 10/6/2026
- Cathie Wood's $22M Biotech Shuffle, Dumps One Stock for 21st Straight Session While Other Bets Pile UpBenzinga · 10/6/2026
Insider Activity
Insider Actions →- Emily M. Leproust · October 5, 2026 · Sale45 @ $207.46
- Emily M. Leproust · October 5, 2026 · Sale146 @ $206.84
- Emily M. Leproust · October 5, 2026 · Sale297 @ $205.78
- Emily M. Leproust · October 5, 2026 · Sale290 @ $204.8
- Emily M. Leproust · October 5, 2026 · Sale432 @ $203.61
- Emily M. Leproust · October 5, 2026 · Sale1.0K @ $202.32
- Emily M. Leproust · October 5, 2026 · Sale481 @ $201.26
- Emily M. Leproust · October 5, 2026 · Sale1.8K @ $200.44
- Emily M. Leproust · October 2, 2026 · Sale45.7K @ $188.88
- WERNER ROBERT F. · October 2, 2026 · Sale1.5K @ $188.88
- Laponis Adam · October 2, 2026 · Sale8.1K @ $188.88
- Green Paula · October 2, 2026 · Sale10.1K @ $188.88
- Finn Patrick John · October 2, 2026 · Sale25.7K @ $188.88
- Cho Dennis · October 2, 2026 · Sale9.5K @ $188.88
- Emily M. Leproust · October 1, 2026 · Sale655 @ $200
Institutional Ownership
March 31, 2026
- Total shares held
- 73.97M
- Total value held
- $3.43B
- Institutional holders
- 273
- Unknown6.37M
- Unknown6.34M
- Unknown5.55M
- Unknown5.38M
- Unknown5.27M
- Unknown3.67M
- Unknown2.64M
- Unknown2.17M
- Unknown1.89M
- Unknown1.71M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Twist Bioscience highlighted in AI biofoundry and analyst upgrades
Recent coverage places Twist Bioscience at the center of AI‑driven biofoundry platforms and synthetic antibody library development. Analyst TD Cowen raised its price target to $190, reflecting confidence in the company’s role in these growing markets. The stock also appeared in a portfolio update and a whale‑alert list, indicating heightened investor attention.
Twist Bioscience highlighted in AI biofoundry and analyst upgrades. Recent coverage places Twist Bioscience at the center of AI‑driven biofoundry platforms and synthetic antibody library development. Analyst TD Cowen raised its price target to $190, reflecting confidence in the company’s role in these growing markets. The stock also appeared in a portfolio update and a whale‑alert list, indicating heightened investor attention.